Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:02:41 EDT Fri 19 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:IVBIY
- INNOVENT BIOLOGICS INC UNSPON ADS EACH REP 4 ORD SHS -
Website unknown - click to update
23:02:41 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
IVBIY
- Q
not subscribed
19.48
0.03
0
2
24.14 18.66
11:38:56
Apr 07
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market:
OTC Markets
-- Tier:
OTC Pink Current
-- Status:
Active
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Portfolio
Recent Trades - All 2 today
More trades...
Time ET
Ex
Price
Change
Volume
11:38:56
Q
14.51
-4.97
25
10:57:05
Q
19.60
0.12
5
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-04-07 20:00
U:IVBIY
News Release
200
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
2024-04-02 01:00
U:IVBIY
News Release
200
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2024-03-26 20:00
U:IVBIY
News Release
200
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
2024-03-20 07:41
U:IVBIY
News Release
200
Innovent Announces 2023 Annual Results and Business Updates
2024-03-18 20:00
U:IVBIY
News Release
200
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
2024-03-11 20:00
U:IVBIY
News Release
200
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
2024-03-06 22:41
U:IVBIY
News Release
200
Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
2024-03-05 00:32
U:IVBIY
News Release
200
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
2024-02-29 19:00
U:IVBIY
News Release
200
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Ralpha/TSLP bispecific antibody) in Australia
2024-02-19 19:21
U:IVBIY
News Release
200
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
2024-02-07 03:35
U:IVBIY
News Release
200
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
2024-02-05 03:41
U:IVBIY
News Release
200
Innovent Announces Retirement of CFO and Appointment of New CFO
2024-01-08 19:00
U:IVBIY
News Release
200
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
2024-01-01 19:00
U:IVBIY
News Release
200
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
2023-12-27 19:00
U:IVBIY
News Release
200
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
2023-12-26 19:00
U:IVBIY
News Release
200
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
2023-12-18 19:00
U:IVBIY
News Release
200
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
2023-12-17 19:00
U:IVBIY
News Release
200
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
2023-12-12 23:51
U:IVBIY
News Release
200
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT ‚ ® 's Seventh Indication and BYVASDA ‚ ®'s Eighth Indication
2023-12-06 20:00
U:IVBIY
News Release
200
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study